Europe is expected to grow significantly in the generic pharmaceuticals market during the forecast period. The low cost of generic pharmaceuticals, rising patent expiration, increasing awareness about generics, and presence of key players drive the market. The program can help to understand the FDA’s understanding of generic drugs and develop advanced methods to characterize product quality and performance. Generics account for 91% of prescriptions dispensed in the U.S. but only 18% of the total drug costs, making them a vital part of the US healthcare system.
Top Key Players In Diabetes Drugs Market
How is the Inflation Reduction Act (IRA) affecting the U.S. generic market? Between 2025 and 2030, major drugs facing patent expiry include Merck’s Keytruda, Johnson & Johnson’s Stelara, and Bristol Myers Squibb’s Eliquis, representing over $200 billion in branded sales at risk.20 Regulatory agencies require generic drug manufacturers to conduct studies demonstrating that their product is bioequivalent to the brand-name reference drug. A generic drug is an exact chemical copy of a small-molecule, chemically synthesized brand-name drug. Forecasts vary, but a synthesized analysis suggests the market will grow from a baseline of approximately $450-$500 billion in the mid-2020s to over $700-$800 billion by the early 2030s, with a compound annual growth rate (CAGR) between 5% and 8%.1
Global Market Dynamics: Size, Scope, And Trajectory
Over the globe, an exceptionally rising aging population with chronic diseases, prone to less mobility, who require long-term treatment, makes home healthcare a helpful option for these patients. As well as this online access for medication, which is often with door-to-door delivery, is significantly driving market growth, especially for people with restricted mobility or those in rural areas. Nowadays, customers are looking for more convenient approaches to access drugs, in which retail pharmacies are playing a major role. This is one of the major drivers for this segment; another factor is technological advancements in biotechnology and personalized medicine, which result in the development of highly efficient treatments. Patients prefer branded drugs because of their recognized quality, efficacy, or familiarity with the brand names.
Although prescription opioid-involved deaths rates have remained relatively stable, it is important to remember what role prescription drug-control policies had in shaping the nature of today’s drug markets . Among the many unintended consequences of such restrictions on prescribing practices included the growth of illicit drug market with counterfeit pills, heroin, and eventually fentanyl . An undisputable contributing factor to this overdose crisis is prescription opioids, which were widely available at the turn of the century and coupled with insufficient regulation of the pharmaceutical and healthcare industries . Darknet markets can be used by local drug dealers and manufacturers to buy precursor substances, but are also attractive for people who use drugs (PWUD) as they offer a comprehensive range of drugs.
KEY INDUSTRY DEVELOPMENTS:
Indeed, it is much more likely that a complex entanglement of economic and structural factors resulted in the unprecedented drug market shift towards synthetic opioids. Nitazenes and fentanyl-analogues, several times more potent than fentanyl itself, are increasingly detected in toxicological testing and have the potential of becoming the drugs of choice in the future. Previously perceived as contaminants, novel synthetic opioids became the drugs of choice and a trend towards higher potency was observed across various substance classes. The emergence of fentanyl on North American street markets from 2014 onwards led to a shift of street drug use patterns. This paper summarises the distinct drug market trends observed locally and internationally over the past decade to extrapolate future drug market trajectories.
Reporting Countries
This process allows generic manufacturers to gain approval by demonstrating that their product is bioequivalent to an already-approved brand-name drug, forgoing the need for duplicative, large-scale clinical trials.14 The system is funded in part by the Generic Drug User Fee Amendments (GDUFA), which provide the FDA with resources to hire reviewers and modernize its processes, with the goal of expediting the review of generic drug applications.25 The convergence of these innovations—complex products, advanced manufacturing, and digital commercial models—is creating a profound divergence within the generic drug industry. The most significant and lucrative frontier in the off-patent market is the development of biosimilars. Because fewer companies possess the technical expertise and capital to overcome them, the competitive landscape for complex generics is less crowded, allowing successful entrants to command higher prices and achieve greater profitability.38 It must be the foundation upon which any successful generic drug business is built.
North America dominated the market in 2024 due to a well-established healthcare infrastructure, high adoption of cost-effective medications, and a strong presence of major generic drug manufacturers. Additionally, the expansion of healthcare infrastructure, adoption of specialty generics, and government initiatives to improve hospital-based drug accessibility are driving growth, making hospital pharmacies a rapidly expanding distribution channel. Additionally, aging populations and lifestyle-related risk factors further boost demand, making cardiovascular generics a high-growth therapeutic segment during the forecast period.
Germany’s emphasis on innovation, biosimilar adoption, and health insurance reimbursement policies has fostered a competitive and high-value prescription drugs environment. Factors such as an aging population, strong healthcare infrastructure, and technological advancements in drug delivery contribute to sustained growth. The hospital pharmacy segment led the market with a share of 42.1% in 2024, due to centralized drug dispensing and institutional procurement. The hospital segment held the largest market share of 48.7% in 2024, supported by high patient volume, availability of advanced therapies, and inpatient prescriptions. The market is segmented on the basis of type, therapy area, route of administration, end user, and distribution channel This report forecasts revenue growth at country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033.
- Furthermore, funding supports generic drug manufacturers in expanding their market reach and distribution networks.
- Thus, off-patent, off-exclusivity drugs play a crucial role in the generic drugs market by promoting competition, affordability, and treatment access.
- Hospitals increasingly consolidate purchasing consortia to extract further discounts, while voluntary influx of low-cost players from India intensifies competition.
- Because chronic diseases are so common, the government and many pharmaceutical companies are expanding their R&D spending to find novel compounds and improve existing technology.
- The booklet opens with a look at the 2022 Taliban ban on the cultivation and production of and trafficking in drugs in Afghanistan and its implications both within the country and in transit and destination markets elsewhere.
The increasing population is also expected to aid the growth of the vaccines segment due to the increasing need for timely vaccinations, especially in infants and children. Further, the rising number of regulatory approvals for targeted therapies in the treatment of cancer is another factor contributing to the segmental growth. The oncology segment is anticipated to dominate the therapy segment due to the increasing prevalence of cancer and the high costs attributed to the treatment of the various forms of cancer. In terms of therapy, the market is segmented into oncology, central nervous system, vaccines, immunosuppressants, and others. The orphan segment is anticipated to grow at a comparatively higher CAGR over the forecast period.
Expanding healthcare infrastructure, government initiatives promoting affordable medicines, and a strong base of local generic manufacturers further fuel growth. Additionally, numerous patent expirations of high-revenue branded drugs in the U.S. have enabled rapid entry of generics. The retail pharmacies segment held the highest market share in 2024 because they provides convenient access to a wide range of generic medications for patients. Injectable generics, including insulin, vaccines, and oncology drugs, are gaining popularity because they provide rapid and targeted therapeutic effects. Increasing awareness about affordable treatment options and the availability of multiple generic versions of key cardiovascular drugs, such as statins and beta-blockers, is driving adoption.
About The Pharmaceuticals Market
- First is the embrace of complexity, both in product development and regulatory navigation.
- The demand for drugs through prescription is increasing across the country owing to rising chronic disease prevalence among the population.
- Two major companies, Novartis and Pfizer, with their strong and diverse product portfolio and presence in key therapeutic areas, such as oncology and vaccines, are prominent reasons responsible for their dominance.
- The generics and biosimilars have a market share of only 25% in Switzerland, while it is 70% in the entire Europe.
- The demand for cannabis around the world, coupled with the drug’s relative ease of cultivation, makes the illicit cannabis trade one of the primary ways in which organized criminal groups finance many of their activities.
- Large-scale drug trafficking is one of the capital crimes, and may result in a death sentence prescribed at the federal level when it involves murder.
Biosimilars, despite accounting for a smaller slice, delivered an 8.20% forecast CAGR thanks to favorable policy reforms in Europe and Japan that expedite interchangeability decisions. Capital-intensive upgrades—such as isolation technology, real-time environmental monitoring, and advanced analytical platforms—raise fixed-cost burdens for sterile sites. Hospitals increasingly consolidate purchasing consortia to extract further discounts, while voluntary influx of low-cost players from India intensifies competition. Streamlined comparability protocols in the EU and imminent Japanese fast-track designations shorten development timelines, while tender systems ensure rapid payer uptake.
World Drug Report 2024
The demand for generic drugs, which serve as an alternative to branded drugs, has increased tremendously owing to their low costs. Thus, the growing utilization of generic drugs is driven by a combination of factors, including safety and efficacy, cost-effectiveness, improved healthcare access, and increased awareness. The increasing emphasis on cost containment and value-based healthcare has further driven the utilization of generic drugs. The growing utilization of generic drugs is a significant opportunity in the pharmaceutical market. The rising prevalence of diabetes and increasing healthcare costs of diabetes treatment necessitate the use of generic drugs. These figures highlight the affordability and cost-effectiveness of generic drugs, making them an important component of healthcare cost management.
The cancer segment is anticipated to grow with the fastest CAGR in the generic pharmaceuticals market during the studied years. The most common therapeutic areas for generic drugs include oncology, central nervous system disorders, anti-infectives, and gastrointestinal disorders. Hence, the rising healthcare costs increase the demand for generics.
Generic Drugs Market Analysis By Mordor Intelligence
A top-down model rebuilt global generic spending by applying molecule-level patent expiry schedules to branded drug sales, adjusting for typical penetration and price-decline patterns, and then allocating by therapy, route, and region. Nevertheless, inflation-linked input costs and upcoming price negotiation clauses will test profitability, pressuring companies to automate quality control, diversify suppliers, and optimize route-to-market economics. North America contributed 33.20% of 2024 global revenue, underpinned by mature substitution policies whereby generics fill more than 90% of prescriptions yet absorb only 18% of spend. India supplies 20% of global generics volume and 60% of global vaccine demand, while China’s volume-based procurement tenders continue resetting global benchmark prices. First-time generics secured under these timelines often capture lucrative six-month exclusivity, allowing sponsors to recoup development costs quickly before price erosion sets in. This issue brief examines trends related to market size measured via sales revenues and volume of prescription drug use between the U.S. and other countries between 2017 and 2023.
Manufacturers adept at patent-litigation analytics can preload product and capture first-year market shares above 35% for newly unblocked molecules. The Federal Trade Commission campaign against “junk patents” threatens to accelerate generic entry for 20 high-value brands, potentially adding USD 5-7 billion in annual U.S. generic revenue by 2027. Recent state legislation mandating e-prescription use bolsters digital channel uptake, while regulatory clarifications on telehealth prescribing post-COVID-19 elevate mail-order volumes. Hospitals and clinics generated 47.80% of revenue in 2024, leveraging group purchasing contracts and value-based formularies that prioritize lowest acquisition cost while safeguarding supply reliability. Uptake already surpasses 50% of eligible treatment days in major European markets, saving payers USD 7 billion in 2023 alone. Oncology generics, projected to grow at 9.21% CAGR, are gaining structural support from biosimilar monoclonal antibodies targeting HER2-positive breast cancer, colorectal cancer, and hematologic malignancies.
